A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

@article{Tan2020ASS,
  title={A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction},
  author={Chee Wah Tan and Wan Ni Chia and Xijian Qin and Pei Liu and Mark I-Cheng Chen and Charles Tiu and Zhiliang Hu and Vivian Chih-Wei Chen and Barnaby Edward Young and Wan Rong Sia and Yee-Joo Tan and Randy Foo and Yongxiang Yi and David Chien Boon Lye and Danielle E. Anderson and Lin‐Fa Wang},
  journal={Nature Biotechnology},
  year={2020},
  pages={1 - 6}
}
A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy during clinical trials and after large-scale vaccination. The current gold standard is the conventional virus neutralization test requiring live pathogen and a biosafety level 3 laboratory. Here, we report a SARS-CoV-2 surrogate virus neutralization test that detects total immunodominant… 
Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD
TLDR
The results show that the performance of sVNT dramatically improves when the intact RBD from the Wuhan-Hu-1 virus variant is used as the plate coating reagent, and the HRP-conjugated soluble ACE2 is use as the detection reagent.
A simple protein-based surrogate neutralization assay for SARS-CoV-2
TLDR
A safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike protein receptor binding domain (RBD) with its receptor, angiotensin converting-enzyme 2 (ACE2).
A simple protein-based surrogate neutralization assay for SARS-CoV-2
TLDR
A safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike protein receptor binding domain (RBD) with its receptor, angiotensin-converting enzyme 2 (ACE2).
A Label-Free SARS-CoV-2 Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients
TLDR
This study is the first to provide longitudinal neutralizing antibody titers beyond 200 days post symptom onset, and despite the decline of IgG concentration andneutralizing antibody titer, IgG avidity index increases, reaches a plateau and then remains constant up to 8 months post-infection.
Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses
TLDR
A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination.
Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses.
TLDR
A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination.
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma
TLDR
A cell-free quantitative neutralization assay based on the competitive inhibition of trimeric SARS-CoV-2 spike protein binding to the angiotensin-converting enzyme 2 (ACE2) receptor that matches the performance of the gold standard live virus infection assay.
Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
TLDR
The results show that the surrogate virus-neutralization test (sVNT) holds promise in detecting RBD-binding antibodies in multiple species, however it lacked sensitivity to detect low titers.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
TLDR
Results, which reveal the early kinetics of Sars-CoV-2 antibody responses, support using the RBD antigen in serological diagnostic assays and RBD-specific antibody levels as a correlate of SARS-Co V-2 neutralizing antibodies in people.
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
TLDR
A robust pseudovirus-based neutralization assay for SARS-CoV-2 is established and is glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
TLDR
Most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity, and rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
TLDR
It is demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2, and there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection.
A serological assay to detect SARS-CoV-2 seroconversion in humans
TLDR
A serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters and can be adjusted to detect different antibody types in serum and plasma.
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
TLDR
It is shown that the SARS-CoV-2 spike protein is less stable than that of SARS -CoV, and limited cross-neutralization activities between SARS and COVID-19 patients’ sera showlimited cross- neutralization activities, suggesting that recovery from one infection might not protect against the other.
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
TLDR
It is demonstrated that most PCR-confirmed SARS-CoV-2–infected persons seroconverted by 2 weeks after disease onset, and validated and tested various antigens in different in-house and commercial ELISAs, finding that commercial S1 IgG or IgA ELISA were of lower specificity, and sensitivity varied between the 2 assays; the IgAELISA showed higher sensitivity.
The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins
TLDR
It is revealed that some MAbs neutralized cell-attached virus efficiently, indicating that they can neutralize by inhibiting the infection process after virus attachment, and several G 1-reactive MAbs displayed low level post-adsorption activity, suggesting they may be capable of inhibiting RVFV infectivity at different stages of the replication cycle.
...
1
2
3
4
...